Genexine Inc (095700.KQ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · South Korea · ISIN KR7095700001
Genexine Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.93 bn KRW | 4.57 bn KRW |
| Gross profit | -1.24 bn KRW | -385.72 m KRW |
| Operating income | -36.94 bn KRW | -36.07 bn KRW |
| EBIT | -62.77 bn KRW | -24.77 bn KRW |
| Net income | -63.71 bn KRW | -27.22 bn KRW |
| Diluted EPS – continuing operations | -1,400.75 KRW | -598.40 KRW |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Genexine Inc
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes. The company is also developing GX-188E that is in Phase II clinical trials for the treatment of cervical cancer, and head and neck cancer. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is headquartered in Seoul, South Korea.
More stocks
- Eco World International Bhd (5283.KL)
- XTRA-GOLD RESOURCES CORP (XTGRF)
- RF Systems Co., Ltd. (474610.KQ)
- Tekcore Co. Ltd (3339.TWO)
- Foodie Media Berhad (0382.KL)
- Semyung Electric Machinery Co.Ltd (017510.KQ)
- Opticore Co., Ltd. (380540.KQ)
- Powertech Industrial Co Ltd (3296.TW)
- NICE Total Cash Management Co. Ltd (063570.KQ)
- Syngen Biotech Co.,Ltd. (8279.TWO)
- Gloo Holdings, Inc. (GLOO)
- Phoenix Vega Mezz PLC (PVMEZZ.AT)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.